Have a feature idea you'd love to see implemented?
Let us know!
CTKB Cytek Biosciences Inc
Price (delayed)
$6.46
Market cap
$832.12M
P/E Ratio
0.01
Dividend/share
N/A
EPS
$940.91
Enterprise value
$678.81M
Highlights
Cytek Biosciences's EPS has soared by 115% YoY and by 115% from the previous quarter
The net income is up by 42% since the previous quarter and by 28% year-on-year
The quick ratio has contracted by 14% from the previous quarter and by 10% YoY
Cytek Biosciences's equity has decreased by 7% YoY
Key stats
What are the main financial stats of CTKB
Market
Valuations
Earnings
Shares outstanding
128.81M
Market cap
$832.12M
Enterprise value
$678.81M
Price to earnings (P/E)
0.01
Price to book (P/B)
2.2
Price to sales (P/S)
4.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.37
Revenue
$201.21M
EBIT
-$10.82M
EBITDA
-$649,000
Free cash flow
$28.68M
Per share
Balance sheet
Liquidity
EPS
$940.91
Free cash flow per share
$0.22
Book value per share
$2.93
Revenue per share
$1.54
TBVPS
$3.47
Total assets
$491.23M
Total liabilities
$105.76M
Debt
$8.99M
Equity
$385.46M
Working capital
$327.39M
Debt to equity
0.02
Current ratio
6.21
Quick ratio
5.26
Net debt/EBITDA
236.23
Margins
Efficiency
Dividend
EBITDA margin
-0.3%
Gross margin
54.9%
Net margin
-5%
Operating margin
-11.8%
Return on assets
-2.1%
Return on equity
-2.6%
Return on invested capital
-4.6%
Return on capital employed
-2.5%
Return on sales
-5.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTKB stock price
How has the Cytek Biosciences stock price performed over time
Intraday
5.38%
1 week
0.62%
1 month
25.68%
1 year
4.36%
YTD
-29.17%
QTD
16.61%
Financial performance
How have Cytek Biosciences's revenue and profit performed over time
Revenue
$201.21M
Gross profit
$110.5M
Operating income
-$23.65M
Net income
-$10.16M
Gross margin
54.9%
Net margin
-5%
The net margin has grown by 44% from the previous quarter and by 35% YoY
The net income is up by 42% since the previous quarter and by 28% year-on-year
The operating margin has grown by 22% YoY and by 10% from the previous quarter
CTKB's operating income is up by 14% YoY and by 8% from the previous quarter
Growth
What is Cytek Biosciences's growth rate over time
Valuation
What is Cytek Biosciences stock price valuation
P/E
0.01
P/B
2.2
P/S
4.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.37
Cytek Biosciences's EPS has soared by 115% YoY and by 115% from the previous quarter
Cytek Biosciences's equity has decreased by 7% YoY
CTKB's price to book (P/B) is 4.3% lower than its last 4 quarters average of 2.3
The company's revenue rose by 10% YoY
The P/S is 6% below the last 4 quarters average of 4.5
Efficiency
How efficient is Cytek Biosciences business performance
Cytek Biosciences's return on equity has increased by 41% QoQ and by 21% YoY
Cytek Biosciences's return on assets has increased by 40% QoQ and by 22% YoY
Cytek Biosciences's ROS has increased by 27% from the previous quarter and by 27% YoY
The return on invested capital is up by 23% since the previous quarter and by 10% year-on-year
Dividends
What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTKB.
Financial health
How did Cytek Biosciences financials performed over time
CTKB's current ratio is down by 15% since the previous quarter and by 14% year-on-year
The quick ratio has contracted by 14% from the previous quarter and by 10% YoY
The debt is 98% less than the equity
The debt to equity has contracted by 33% YoY
The debt has contracted by 24% YoY and by 4.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.